Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The granulocyte-macrophage colony-stimulating factor receptor (GM-CSFR) beta subunit (βc or CD131) is a critical component of the GM-CSFR complex, which mediates the effects of GM-CSF on myeloid cells. It is essential for high-affinity ligand binding and signal transduction. As a shared subunit for IL-3 and IL-5 receptors, it represents an attractive therapeutic target for modulating immune responses in diseases involving dysregulated myelopoiesis or inflammation. Activation of this receptor leads to JAK/STAT signaling and influences myeloid cell proliferation, differentiation, and survival. Downregulation mechanisms include SHP‑1/SOCS-mediated inhibition, degradation, and internalization. Mutations affecting this receptor can lead to constitutive activation and dysregulation, implicated in disease pathogenesis, including leukemias.
Modulation of cytokine signaling via receptor blockade or inhibition of downstream signaling pathways (e.g., JAK/STAT)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Granulocyte-macrophage colony-stimulating factor receptor beta subunit.